Evolution of Ocular Neovascular Therapy

Ocular neovascular diseases now benefit from evolving non-intravitreal anti-VEGF delivery methods that reduce clinical burden. Traditionally, intravitreal injections have served as the gold standard for managing retinal and choroidal vascular conditions. However, the long-term reliance on frequent, repeated injections imposes significant physical and financial stress on patients. Furthermore, real-world data often shows that patients achieve poorer visual outcomes compared to those in controlled clinical trials due to suboptimal adherence.

Overcoming Barriers in Non-Intravitreal Anti-VEGF Delivery

Researchers are actively exploring diverse routes to deliver medication without entering the vitreous directly. Specifically, non-intravitreal anti-VEGF delivery through the suprachoroidal space allows for higher drug concentrations in the choroid and retinal pigment epithelium. This route bypasses many traditional ocular pharmacokinetic barriers that previously limited drug efficacy. Additionally, systemic, transscleral, and topical strategies offer varied levels of maturity. Although topical eye drops provide maximum convenience, they currently struggle with low bioavailability in the posterior segment. Consequently, scientists are developing novel nanocarriers to enhance penetration across the corneal and scleral barriers.

Gene-Based Strategies and Future Directions

Gene-based therapies represent a significant leap toward sustained VEGF suppression. These platforms essentially turn the eye\'s own cells into bio-factories that produce therapeutic proteins. This one-time treatment model could eliminate the need for monthly clinic visits. Moreover, clinical trials for viral and non-viral vectors delivered suprachoroidally show encouraging safety profiles. While intravitreal therapy remains the current benchmark, the shift toward localized, durable, and less invasive delivery is accelerating. These advancements aim to harmonize therapeutic efficacy with a manageable treatment schedule for aging populations.

Frequently Asked Questions

What are the main benefits of non-intravitreal delivery?

The primary advantage is the reduction of treatment burden. By using alternative routes, clinicians can decrease the frequency of invasive injections, which improves patient compliance and potentially leads to better real-world visual outcomes.

Why is topical anti-VEGF delivery currently limited?

Topical delivery faces significant anatomical and physiological barriers, such as tear turnover and the corneal epithelium. Only a very small fraction of the drug reaches the posterior segment, making it difficult to maintain therapeutic levels without advanced formulation technologies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Joshi SM et al. Non-intravitreal anti-vascular endothelial growth factor delivery for ocular neovascular diseases: Current status and future directions. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_3226_25. PMID: 42060354.

2. Chiang B, et al. Suprachoroidal Drug Delivery for VEGF Suppression in Wet AMD and Other Diseases With Choroidal Neovascularization. Am J Ophthalmol. 2025;272:125-134.

3. Wang J, et al. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. Front Pharmacol. 2023;14:1112357.